Connecticut has placed its second $1 million bioscience bet in two weeks, this time in a New Haven genetic-research startup, MiraDx.
Connecticut Innovations (CI) Inc. in Rocky Hill, the state’s quasi-public technology investment arm, said Thursday it participated in a $4 million investment round involving individual investors. CI also gets a seat on the MiraDx board.
CI said MiraDx has licensed micro-RNA discoveries from Yale University to come up with a genetic roadmap for determining the likelihood of certain diseases occurring in individuals and their response to certain therapies.
Working from its own lab, MiraDx is collaborating its research with physicians, hospitals and health centers.
One of its products close to introduction is aimed at screening women for the genetic marker for a risk of ovarian cancer,
In mid-June, CI invested $1 million to lure EpiEP Inc., a small Virginia biomedical company with five workers, to New Haven in hopes for a payoff from EpiEP’s device to make heart surgeries less invasive.
